Lataa...
Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy
BACKGROUND: Burosumab, a recombinant anti-FGF23 monoclonal antibody, was recently introduced as a treatment for X-linked hypophosphatemia (XLH). Burosumab normalizes blood phosphate levels, thereby healing rickets, decreasing leg bowing, and reducing pain. We aimed to explore the body composition an...
Tallennettuna:
| Julkaisussa: | Ther Adv Endocrinol Metab |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970173/ https://ncbi.nlm.nih.gov/pubmed/33796255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20420188211001150 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|